Jasmine M. Zain

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Elise A. Olsen, Sean Whittaker, Rein Willemze et al. · Blood · 2021 · 171 citations · Full text

Medicine, Dermatology, Oncology +11

Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study

Swaminathan P. Iyer, R. Alejandro Sica, P. Joy Ho et al. · The Lancet Oncology · 2024 · 72 citations · Full text

Life Sciences, Immunology, Oncology +15

Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Auris Huen, Bradley M. Haverkos, Jasmine M. Zain et al. · Cancers · 2020 · 63 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +15

Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant

Monzr M. Al Malki, Ni‐Chun Tsai, Joycelynne Palmer et al. · Blood Advances · 2021 · 61 citations · Full text

Medicine, Hematology, Immunology +17

Aggressive T‐cell lymphomas: 2021 Updates on diagnosis, risk stratification and management

Jasmine M. Zain, Paul Hanona · American Journal of Hematology · 2021 · 43 citations · Full text

Medicine, Molecular Medicine, Oncology +17